RESEARCH

Protein Kinase Inhibitor Development

"Kinome" is a depository of promising drug targets - protein kinases, which control vast diversity of molecular interactions in cell life. Indeed, numerous reports describing the discovery of new pharmaceutical substances targeting protein kinases have been published during last few years. Some of these substances are being tested in clinical trials, some of them are already on the market.

Our Department has been involved in extensive research and development of inhibitors for various protein kinases:

(thieno[2,3-d]pyrimidin-4-ylthio)carboxylic acids (TTP)

Figure 1. The binding mode of TTP22 in the CK2 active site. Hydrogen bonds are shown by the dotted lines.

To study CK2 inhibitory activity of substituted (thieno[2,3-d] pyrimidin-4-ylthio)carboxylic acids, 28 compounds of this class were synthesized and tested in vitro. The most active...

Other kinase inhibitors research:

ASK1 Inhibitors

Identification of 3H-naphtho[1,2,3-de]quinoline-2,7-diones as Inhibitors of ASK1

Virtual screening and biochemical screening allowed us to identify...

CK2 Inhibitors

(thieno[2,3-d]pyrimidin-4-ylthio)carboxylic acids (TTP)

To study CK2 inhibitory activity of substituted (thieno[2,3-d]...

FGFR1 Inhibitors

Flavones

One of the first discovered in the screening of inhibitors of FGFR1 classes are...